Clinical Study the Efficacy and Safety of Rh-EPO in the Treatment of Anemia in Lymphoma
Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
The incidence of lymphoma and anemia is high and the clinical harm is great.However, it has
not yet attracted enough clinical attention, and domestic rHuEPO (trade name: Ebio).Shenyang
Sansheng Pharmaceutical Co., Ltd.) for lymphoma and anemia patients are less clinical
studies.Therefore, a prospective, open-label, multicenter clinical study of recombinant human
erythropoietin in the treatment of anemia in patients with lymphoma is planned to analyze the
efficacy and safety of recombinant human erythropoietin in patients with lymphoma and anemia,
so as to determine the clinical benefits of recombinant human erythropoietin in patients with
lymphoma and anemia.
Phase:
Phase 3
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborators:
First Affiliated Hospital of Jiaxing University First Affiliated Hospital of Wenzhou Medical University First People's Hospital of Hangzhou Ningbo Medical Center Lihuili Hospital Second Affiliated Hospital of Wenzhou Medical University Taizhou Hospital of Zhejiang Province The First Affiliated Hospital of Zhejiang Chinese Medical University Wenzhou Central Hospital Zhejiang Cancer Hospital Zhejiang Provincial Tongde Hospital